US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mira Pharma

0.9389

-0.1311-12.25%

Post-market: 0.9297-0.0092-0.98%19:59 EDT

Volume:1.83M

Turnover:1.65M

Market Cap:15.79M

PE:-1.85

High:0.9900

Open:0.9900

Low:0.8300

Close:1.07

Loading ...

Overview Company News Filings

Top Midday Gainers

MT Newswires Live

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

ACCESS Newswire

BRIEF-Mira Pharmaceuticals Inc - Announces Positive Study Results For Ketamir-2

Mira Pharmaceuticals Inc - Announces Positive Study Results for Ketamir-2 - SEC Filing

THOMSON REUTERS

Mira Pharmaceuticals Inc - to Initiate Phase Iia Trial in Diabetic Neuropathy Patients by End of 2025

THOMSON REUTERS

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study

MIRA Continues Positive Testing Run

Zacks Small Cap Research

Mira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2

BRIEF-Mira Pharmaceuticals Inc - Enrolls First Subjects In Phase 1 Trial For Ketamir-2 - SEC Filing

Mira Pharmaceuticals Inc - First Human Efficacy Data Expected in H1 2026

THOMSON REUTERS

Mira Pharmaceuticals Inc - Phase 1 Study Expected to Complete by Q4 2025 - SEC Filing

THOMSON REUTERS

Miramar's shareholders block $401 million deal to buy Henderson Land's unit

Chains of War ($MIRA) Shows Remarkable Growth Trajectory with a 1-Month Surge of 2965.37%

Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit

Mira Pharmaceuticals Shares Down 3% After All-Stock Deal for Skny Pharma

THOMSON REUTERS

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Pinterest, IBM

BUZZ-MIRA Pharma falls on all-stock deal for SKNY Pharma

Mira Pharmaceuticals Signs LOI to Acquire Skny Pharmaceuticals

MT Newswires Live

BRIEF-Mira Pharmaceuticals Inc To Acquire Skny Pharmaceuticals - SEC Filing

Mira Pharmaceuticals signs binding LOI to acquire SKNY Pharmaceuticals

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MIRA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MIRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":0.9389,"timestamp":1744920000000,"preClose":1.07,"halted":0,"volume":1830468,"hourTrading":{"tag":"盘后","latestPrice":0.9297,"preClose":0.9389,"latestTime":"19:59 EDT","volume":55165,"amount":49954.0456,"timestamp":1744934347758},"delay":0,"floatShares":11764337,"shares":16813654,"eps":-0.508455,"marketStatus":"Market Closed","change":-0.1311,"latestTime":"04-17 16:00:00 EDT","open":0.99,"high":0.99,"low":0.83,"amount":1646432.5642332,"amplitude":0.149533,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.508455,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":1.07,"preHourTrading":{"tag":"盘前","latestPrice":0.97,"preClose":1.07,"latestTime":"09:29 EDT","volume":88575,"amount":84899.261505,"timestamp":1744896590002},"postHourTrading":{"tag":"盘后","latestPrice":0.9297,"preClose":0.9389,"latestTime":"19:59 EDT","volume":55165,"amount":49954.0456,"timestamp":1744934347758},"volumeRatio":0.1889272963167111},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","floatShares":11764337,"roa":"-127.59%","roe":"-238.90%","lyrEps":-0.508455,"volumeRatio":0.1889272963167111,"shares":16813654,"dividePrice":0,"high":0.99,"amplitude":0.149533,"preClose":1.07,"low":0.83,"week52Low":0.51,"pbRate":"7.18","week52High":5.01,"institutionHeld":0,"latestPrice":0.9389,"eps":-0.508455,"divideRate":0,"volume":1830468,"delay":0,"ttmEps":-0.508455,"open":0.99,"prevYearClose":1.14,"prevWeekClose":0.8649,"prevMonthClose":0.98,"prevQuarterClose":0.98,"fiveDayClose":0.8436,"twentyDayClose":1.22,"sixtyDayClose":1.19},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MIRA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528275805","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2528275805","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528275805?lang=en_us&edition=fundamental","pubTime":"2025-04-17 02:05","pubTimestamp":1744826711,"startTime":"0","endTime":"0","summary":"RadNet  has agreed to acquire iCad  in an all-stock deal valued at roughly $103 million, they said late Tuesday.Shares of iCad soared 71%, with intraday trading volume of over 17.2 million from a daily average of about 508,000.Treasure Global  struck a partnership with Mezzofy , securing distribution rights for Mezzofy's digital coupon platform in Malaysia. It expects to generate $2 million to $4 million in annual revenue in the first 12 months of the rollout.Shares surged 57% as intraday trading volume soared to more than 92 million from a daily average of about 354,000.Mira Pharmaceuticals  said Wednesday that data demonstrated the potential efficacy of its oral ketamine analog, Ketamir-2, in treating diabetic neuropathy in an animal model.Shares advanced 15%, with intraday trading volume rising to over 44.8 million from a daily average of about 255,000.Price: 50.78, Change: -2.30, Percent Change: -4.33","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4196","TGL","ICAD","LU2065731478.USD","RDNT","MIRA","BK4009","BK4167"],"gpt_icon":1},{"id":"2527221611","title":"MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion","url":"https://stock-news.laohu8.com/highlight/detail?id=2527221611","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527221611?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:00","pubTimestamp":1744804800,"startTime":"0","endTime":"0","summary":"Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal. MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals, Inc. , or MIRA, a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic and neuropsychiatric disorders, today announced compelling data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of diabetic neuropathy.In the study, Type 2 diabetes was induced in rats using a high-fat diet combined with a low dose of Streptozotocin . This resulted in hyperglycemia and neuropathic symptoms, including hyperalgesia and allodynia, mimicking human diabetic pathology. By week 8, most diabetic rats exhibited sensory hypersensitivity. Treatment with Ketamir-2 led to a significant reduction in neuropathic pain symptoms, with some animals returning completely to pre-diabetic baseline sensitivity. \"Millions of patients with dia","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-announces-positive-results-120000582.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","BK4559","BK4504","LU2552382058.USD","STZ","BK4585","LU2552382132.HKD","LU2552382215.SGD","BK4588","BK4007","BK4169"],"gpt_icon":0},{"id":"2527290559","title":"BRIEF-Mira Pharmaceuticals Inc - Announces Positive Study Results For Ketamir-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2527290559","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527290559?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:35","pubTimestamp":1744803308,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Inc - Announces Positive Study Results For Ketamir-2April 16  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - ANNOUNCES POSITIVE STUDY RESULTS FOR KETAMIR-2 - SEC FILINGMIRA PHARMACEUTICALS INC - KETAMIR-2 SHOWS SIGNIFICANT REDUCTION IN NEUROPATHIC PAIN SYMPTOMS - SEC FILINGMIRA PHARMACEUTICALS INC - TO INITIATE PHASE IIA TRIAL IN DIABETIC NEUROPATHY PATIENTS BY END OF 2025Further company coverage: MIRA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU0Y9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2527977472","title":"Mira Pharmaceuticals Inc - Announces Positive Study Results for Ketamir-2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2527977472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527977472?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:31","pubTimestamp":1744803111,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU0Y9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2527829088","title":"Mira Pharmaceuticals Inc - to Initiate Phase Iia Trial in Diabetic Neuropathy Patients by End of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527829088","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527829088?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:31","pubTimestamp":1744803111,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU0Y9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2527297583","title":"EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527297583","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527297583?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:15","pubTimestamp":1744802158,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc.  on Wednesday released data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of diabetic neuropathy,a type of nerve damage that can occur in diabetes patients.In the study, Type 2 diabetes was induced in rats using a high-fat diet combined with a low dose of Streptozotocin .Treatment with Ketamir-2 led to a significant reduction in neuropathic pain symptoms, with some animals returning completely to pre-diabetic baseline sensitivity.Also Read: EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate. MIRA anticipates initiating its Phase 2a trial in diabetic neuropathy by the end of 2025, with the first human efficacy data expected in the first half of 2026.In addition, MIRA is actively conducting ongoing studies assessing the efficacy of Ketamir-2 in models of post-traumatic stress disorder.The transaction includes a $5 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-mira-pharmaceuticals-ketamir-2-111558635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","LU2552382058.USD","BK4169","BK4559","BK4585","LU2552382132.HKD","BK4588","LU2552382215.SGD","MIRA","BK4007","STZ"],"gpt_icon":0},{"id":"2527622534","title":"MIRA Continues Positive Testing Run","url":"https://stock-news.laohu8.com/highlight/detail?id=2527622534","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527622534?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:05","pubTimestamp":1744801500,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals  is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company also acquired the rights to Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ketamine that has shown indications of having fewer side effects, working more rapidly, and having the opportunity to impact millions of patients that have not responded to other, existing treatments. We have written about the exciting preclinical results for Ketamir-2, the company’s novel oral ketamine analog, and the company just announced more positive testing results that build on all of the other positive results seen to this point.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-continues-positive-testing-run-110500207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","BK4585","MIRA","LU2552382132.HKD","LU2552382215.SGD","BK4007","BK4588","BK4559","LU2552382058.USD","STZ","BK4169"],"gpt_icon":0},{"id":"2524163461","title":"Mira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2524163461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524163461?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:37","pubTimestamp":1743511058,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals (MIRA) announced the enrollment of the first subjects in its Phase 1 clinical trial of Ketamir-2, a novel oral ketamine analog...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-enrolls-first-subjects-in-phase-1-trial-of-ketamir-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-enrolls-first-subjects-in-phase-1-trial-of-ketamir-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2524197593","title":"BRIEF-Mira Pharmaceuticals Inc - Enrolls First Subjects In Phase 1 Trial For Ketamir-2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2524197593","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524197593?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:33","pubTimestamp":1743507209,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Inc - Enrolls First Subjects In Phase 1 Trial For Ketamir-2 - SEC FilingApril 1  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - ENROLLS FIRST SUBJECTS IN PHASE 1 TRIAL FOR KETAMIR-2 - SEC FILINGMIRA PHARMACEUTICALS INC - PHASE 1 STUDY EXPECTED TO COMPLETE BY Q4 2025 - SEC FILINGMIRA PHARMACEUTICALS INC - FIRST HUMAN EFFICACY DATA EXPECTED IN H1 2026Source text: [ID:n0001641172-25-001987]Further company coverage: MIRA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF02L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":1},{"id":"2524197337","title":"Mira Pharmaceuticals Inc - First Human Efficacy Data Expected in H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2524197337","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524197337?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:32","pubTimestamp":1743507124,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF02L:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2524197336","title":"Mira Pharmaceuticals Inc - Phase 1 Study Expected to Complete by Q4 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2524197336","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524197336?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:32","pubTimestamp":1743507124,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF02L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2523594854","title":"Miramar's shareholders block $401 million deal to buy Henderson Land's unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2523594854","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523594854?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:33","pubTimestamp":1743420788,"startTime":"0","endTime":"0","summary":"UPDATE 1-Miramar's shareholders block $401 million deal to buy Henderson Land's unitUpdates with details and background from paragraph 2 onwardsMarch 31  - Miramar Hotel and Investment's 0071.HK shareholders rejected the HK$3.12 billion  deal under which it was buying a property from Hong Kong's Henderson Land Development 0012.HK for building a hotel and commercial complex.Over 53% of stockholders voted against the proposed deal, while around 46% supported the transaction, an exchange filing by the hotel operator showed on Monday.Henderson Land and Miramar, in January, unveiled plans to change ownership of the property, with the former scrapping plans for a new commercial tower.Miramar intended to develop a hotel to ease pressure on its popular hotel, The Mira Hong Kong. The property's sale, located at the heart of Hong Kong's Tsim Sha Tsui district, was seen as a major sign of a post-pandemic recovery in the local tourism industry.Henderson Land, which owns just over half of Miramar, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL3N3QE0L5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1601","BK1240","MIRA","BK4007","BK1559","BK1164","00012","00071"],"gpt_icon":0},{"id":"2523463979","title":"Chains of War ($MIRA) Shows Remarkable Growth Trajectory with a 1-Month Surge of 2965.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2523463979","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523463979?lang=en_us&edition=fundamental","pubTime":"2025-03-29 05:54","pubTimestamp":1743198868,"startTime":"0","endTime":"0","summary":"Chains of War ($MIRA) has recently recorded remarkable growth. As per the latest data, Chains of War ($MIRA) went through a 2965.37% increase over the past month. This has gained the attention of the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/67e71a92e283516da47e59ba/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["MIRA","BK4007"],"gpt_icon":1},{"id":"2522076475","title":"Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit","url":"https://stock-news.laohu8.com/highlight/detail?id=2522076475","media":"TipRanks","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522076475?lang=en_us&edition=fundamental","pubTime":"2025-03-25 21:00","pubTimestamp":1742907627,"startTime":"0","endTime":"0","summary":"Stock index futures are experiencing a notable surge, reflecting renewed investor optimism, primarily driven by reports suggesting that the U.S. administration may reduce the scope of proposed tariffs, potentially excluding certain sectors. Such developments have bolstered market sentiment, leading to premarket gains across major indices.Discover stocks' market position with detailed  competitor analyses.In the commodities market, oil prices have experienced a slight decline as investors closely monitor ongoing ceasefire talks between Russia and Ukraine. The anticipation of increased Russian oil supply, contingent upon successful peace negotiations, has exerted downward pressure on prices. Currently, Brent crude futures are trading at $71.91 per barrel, while U.S. West Texas Intermediate crude stands at $68.08 per barrel.Meanwhile, the “Magnificent Seven,” comprising companies like Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Tesla, are poised for a potential rebound","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/morning-movers-23andme-plummets-chapter-130027414.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/morning-movers-23andme-plummets-chapter-130027414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1804176565.USD","BK4123","BK4082","LU0566484027.USD","LU2265009873.SGD","DNB","BK4196","BK4121","BK4534","BK4011","LU1861220207.SGD","BK4007","JHX","LU1559883803.SGD","BK4606","BK4198","BK4141","MEHCQ","ALC","BK4086","LU1861217088.USD","LNSR","MIRA","BK4081","PENG","LU2360107671.USD","ME","AZEK","OKLO"],"gpt_icon":1},{"id":"2521724726","title":"Mira Pharmaceuticals Shares Down 3% After All-Stock Deal for Skny Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2521724726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521724726?lang=en_us&edition=fundamental","pubTime":"2025-03-24 21:44","pubTimestamp":1742823848,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q70W7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2521721082","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Pinterest, IBM","url":"https://stock-news.laohu8.com/highlight/detail?id=2521721082","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521721082?lang=en_us&edition=fundamental","pubTime":"2025-03-24 21:29","pubTimestamp":1742822983,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Pinterest, IBMEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL6N3Q70CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B894F039.SGD","EVS.SI","ME","LU0320764599.SGD","LU0612318971.USD","LU0055631609.USD","IE00B7SZL793.SGD","IE00BK4W5M84.HKD","LU0964807845.USD","IBM","LU2063271972.USD","KVUE","TSLA","IE00B3T34201.USD","VSAT","LU0170899867.USD","LU1064927863.SGD","DNB","BK4570","AZEK","SARO","LU2108987350.USD","LU0792757196.USD","RXST","AU","MIRA","LU0345770308.USD","LU2360106780.USD","LU1674673691.USD","HRI","BK1119","TSYW.SI","BK4538","PINS","JHX.AU","RIO.UK","BK4581","LU0612318385.USD","UCAR","LU0788108826.HKD","LU0345777147.USD","RIO.AU","LU0820561818.USD","MEHCQ","NIO.SI","LU2750360997.AUD"],"gpt_icon":1},{"id":"2521287217","title":"BUZZ-MIRA Pharma falls on all-stock deal for SKNY Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2521287217","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521287217?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:31","pubTimestamp":1742819477,"startTime":"0","endTime":"0","summary":"BUZZ-MIRA Pharma falls on all-stock deal for SKNY Pharma** Shares of Florida-based drug developer MIRA Pharmaceuticals MIRA.O fall 8.6% to $1.17 premarket** Agrees to buy privately held Delaware-based SKNY Pharmaceuticals in a stock deal to add experimental weight-loss drug candidate - regulatory filing ** SKNY-1 is an experimental oral drug in preclinical development for weight-loss and smoking cessation** Says SKNY will contribute $5 million in cash or assets at close ** MIRA marginally up in the past 12 months   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL3N3Q70U8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2521474097","title":"Mira Pharmaceuticals Signs LOI to Acquire Skny Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2521474097","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521474097?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:08","pubTimestamp":1742818121,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals  said Monday it has a signed a binding letter of intent to acquire Skny Pharmaceuticals via a stock transaction.Under the terms of the letter of intent, Skny shareholders will receive shares of Mira common stock at a valuation determined by an independent third party firm, Mira said.The transaction includes a $5 million capital infusion of cash or assets into Mira upon closing.SKNY-1, a preclinical-stage oral drug candidate for weight loss and smoking cessation, and all rela","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MIRA","BK4007"],"gpt_icon":1},{"id":"2521874762","title":"BRIEF-Mira Pharmaceuticals Inc To Acquire Skny Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2521874762","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521874762?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:02","pubTimestamp":1742817739,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Inc To Acquire Skny Pharmaceuticals - SEC FilingMarch 24  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - TO ACQUIRE SKNY PHARMACEUTICALS - SEC FILINGMIRA PHARMACEUTICALS INC - ACQUISITION TO ADD SKNY-1 DRUG CANDIDATE TO MIRA PIPELINESource text: [ID:n0001641172-25-000199]Further company coverage: MIRA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q71E8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2521474736","title":"Mira Pharmaceuticals signs binding LOI to acquire SKNY Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2521474736","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521474736?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:55","pubTimestamp":1742817345,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals (MIRA) has signed a binding letter of intent to acquire SKNY Pharmaceuticals. The transaction includes a $5M capital infusion-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-signs-binding-loi-to-acquire-skny-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-signs-binding-loi-to-acquire-skny-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":63,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MIRA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MIRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MIRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1741233600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MIRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MIRA","date":"2025-04-17","current":-2.291021,"percent":0.298507,"low":-15.501022,"twenty":-3.602316,"median":-1.885876,"eighty":-1.323783,"high":-0.648567,"avg":-3.340109,"sd":3.609323,"marketCap":17990609},"quantilePoints":[{"date":"2023-08-04","current":-15.501022,"twenty":-15.501022,"median":-15.501022,"eighty":-15.501022,"marketCap":109409161},{"date":"2023-08-11","current":-14.407729,"twenty":-14.826558,"median":-14.407729,"eighty":-13.088417,"marketCap":101692488},{"date":"2023-08-18","current":-13.611953,"twenty":-14.407729,"median":-13.779485,"eighty":-13.130299,"marketCap":96075752},{"date":"2023-08-25","current":-13.193124,"twenty":-14.407729,"median":-13.42348,"eighty":-13.109358,"marketCap":93119575},{"date":"2023-09-01","current":-13.137838,"twenty":-14.303022,"median":-13.371126,"eighty":-13.130299,"marketCap":92729360},{"date":"2023-09-07","current":-12.209294,"twenty":-13.9889,"median":-13.365891,"eighty":-13.071664,"marketCap":86175515},{"date":"2023-09-15","current":-7.434221,"twenty":-13.678966,"median":-13.193124,"eighty":-12.686741,"marketCap":52472141},{"date":"2023-09-22","current":-11.507289,"twenty":-13.511434,"median":-13.119829,"eighty":-11.928492,"marketCap":66366173},{"date":"2023-09-29","current":-12.263336,"twenty":-13.419292,"median":-13.046534,"eighty":-11.42538,"marketCap":70726534},{"date":"2023-10-06","current":-12.045492,"twenty":-13.402539,"median":-12.816178,"eighty":-11.507289,"marketCap":69470159},{"date":"2023-10-13","current":-7.586097,"twenty":-13.383691,"median":-12.460173,"eighty":-11.225373,"marketCap":43751419},{"date":"2023-10-20","current":-8.457473,"twenty":-13.371126,"median":-12.263336,"eighty":-10.752267,"marketCap":48776920},{"date":"2023-10-27","current":-6.022746,"twenty":-13.371126,"median":-12.209294,"eighty":-9.627991,"marketCap":34735079},{"date":"2023-11-03","current":-3.818677,"twenty":-13.36275,"median":-12.045492,"eighty":-8.098671,"marketCap":22023518},{"date":"2023-11-10","current":-3.793048,"twenty":-13.343902,"median":-11.968606,"eighty":-7.418465,"marketCap":21875709},{"date":"2023-11-17","current":-6.622011,"twenty":-13.222442,"median":-11.712319,"eighty":-5.991992,"marketCap":49959391},{"date":"2023-11-24","current":-6.405718,"twenty":-13.159952,"median":-11.404903,"eighty":-6.252529,"marketCap":48327581},{"date":"2023-12-01","current":-6.955071,"twenty":-13.133315,"median":-11.148487,"eighty":-6.405718,"marketCap":52472141},{"date":"2023-12-08","current":-3.546106,"twenty":-13.117734,"median":-10.762135,"eighty":-5.961237,"marketCap":26753401},{"date":"2023-12-15","current":-2.977946,"twenty":-13.096793,"median":-9.110163,"eighty":-5.156496,"marketCap":22466945},{"date":"2023-12-22","current":-2.066929,"twenty":-13.063287,"median":-8.611245,"eighty":-3.869935,"marketCap":15593833},{"date":"2023-12-29","current":-2.155092,"twenty":-13.025592,"median":-8.1243,"eighty":-3.839181,"marketCap":16258973},{"date":"2024-01-05","current":-2.272643,"twenty":-12.962768,"median":-7.893642,"eighty":-3.762396,"marketCap":17145826},{"date":"2024-01-12","current":-1.929591,"twenty":-12.874813,"median":-7.640782,"eighty":-3.079823,"marketCap":14557693},{"date":"2024-01-19","current":-1.608482,"twenty":-12.807801,"median":-7.444864,"eighty":-2.883906,"marketCap":12135106},{"date":"2024-01-26","current":-2.292235,"twenty":-12.642964,"median":-7.355439,"eighty":-2.366683,"marketCap":17293635},{"date":"2024-02-02","current":-1.880808,"twenty":-12.498268,"median":-7.111805,"eighty":-2.256969,"marketCap":14189649},{"date":"2024-02-09","current":-1.950359,"twenty":-12.397348,"median":-6.788541,"eighty":-2.206031,"marketCap":14714371},{"date":"2024-02-16","current":-2.01795,"twenty":-12.300188,"median":-6.405718,"eighty":-2.186439,"marketCap":15224311},{"date":"2024-02-23","current":-2.076725,"twenty":-12.241719,"median":-6.022746,"eighty":-2.135501,"marketCap":15667738},{"date":"2024-03-01","current":-1.968971,"twenty":-12.205282,"median":-5.750179,"eighty":-2.104154,"marketCap":14854789},{"date":"2024-03-08","current":-1.86102,"twenty":-12.137755,"median":-4.971969,"eighty":-2.061052,"marketCap":14040362},{"date":"2024-03-15","current":-2.409785,"twenty":-12.045492,"median":-3.957585,"eighty":-2.070847,"marketCap":18180488},{"date":"2024-03-22","current":-2.46856,"twenty":-12.014738,"median":-3.869935,"eighty":-2.084562,"marketCap":18623915},{"date":"2024-03-28","current":-2.135501,"twenty":-11.968606,"median":-3.818677,"eighty":-2.096317,"marketCap":16111164},{"date":"2024-04-05","current":-1.258227,"twenty":-11.958355,"median":-3.592948,"eighty":-2.059093,"marketCap":15076502},{"date":"2024-04-12","current":-1.209008,"twenty":-11.917349,"median":-3.095496,"eighty":-2.037542,"marketCap":14486745},{"date":"2024-04-19","current":-1.033719,"twenty":-11.835337,"median":-3.026925,"eighty":-1.978767,"marketCap":12386381},{"date":"2024-04-26","current":-1.1102,"twenty":-11.507289,"median":-2.977946,"eighty":-1.941738,"marketCap":13302796},{"date":"2024-05-03","current":-0.996589,"twenty":-11.466334,"median":-2.723253,"eighty":-1.872971,"marketCap":11941476},{"date":"2024-05-10","current":-0.925167,"twenty":-11.297339,"median":-2.546927,"eighty":-1.840684,"marketCap":11085663},{"date":"2024-05-17","current":-0.812651,"twenty":-11.251002,"median":-2.419581,"eighty":-1.782849,"marketCap":10043611},{"date":"2024-05-24","current":-1.05244,"twenty":-11.138236,"median":-2.390193,"eighty":-1.612165,"marketCap":13007178},{"date":"2024-05-31","current":-0.956764,"twenty":-11.09723,"median":-2.331418,"eighty":-1.319904,"marketCap":11824708},{"date":"2024-06-07","current":-0.922081,"twenty":-10.81147,"median":-2.30203,"eighty":-1.233679,"marketCap":11396062},{"date":"2024-06-14","current":-0.849247,"twenty":-10.732533,"median":-2.292235,"eighty":-1.18937,"marketCap":10495906},{"date":"2024-06-21","current":-0.875439,"twenty":-10.189973,"median":-2.272643,"eighty":-1.090284,"marketCap":10819607},{"date":"2024-06-28","current":-0.77737,"twenty":-9.841423,"median":-2.272643,"eighty":-1.073193,"marketCap":9607575},{"date":"2024-07-05","current":-0.687674,"twenty":-9.256415,"median":-2.262847,"eighty":-1.05424,"marketCap":8499008},{"date":"2024-07-12","current":-0.717692,"twenty":-8.841445,"median":-2.213868,"eighty":-1.045463,"marketCap":8870009},{"date":"2024-07-15","current":-0.704656,"twenty":-8.774265,"median":-2.213868,"eighty":-1.033719,"marketCap":8708897},{"date":"2024-08-02","current":-2.906169,"twenty":-8.772416,"median":-2.213868,"eighty":-1.036655,"marketCap":35917550},{"date":"2024-08-09","current":-2.535423,"twenty":-8.703509,"median":-2.262847,"eighty":-1.048424,"marketCap":31335476},{"date":"2024-08-16","current":-2.173611,"twenty":-8.390838,"median":-2.272643,"eighty":-1.04904,"marketCap":27788063},{"date":"2024-08-23","current":-2.162049,"twenty":-8.098671,"median":-2.248016,"eighty":-1.051378,"marketCap":27640254},{"date":"2024-08-30","current":-2.162049,"twenty":-7.95515,"median":-2.242981,"eighty":-1.05289,"marketCap":27640254},{"date":"2024-09-06","current":-1.826758,"twenty":-7.791127,"median":-2.23142,"eighty":-1.05469,"marketCap":23353798},{"date":"2024-09-13","current":-1.549276,"twenty":-7.650578,"median":-2.222644,"eighty":-1.05842,"marketCap":19806385},{"date":"2024-09-20","current":-1.341164,"twenty":-7.640782,"median":-2.194276,"eighty":-1.060611,"marketCap":17145826},{"date":"2024-09-27","current":-1.237108,"twenty":-7.586097,"median":-2.16783,"eighty":-1.073193,"marketCap":15815546},{"date":"2024-10-04","current":-1.352726,"twenty":-7.444864,"median":-2.155092,"eighty":-1.083185,"marketCap":17293635},{"date":"2024-10-11","current":-1.24867,"twenty":-7.434221,"median":-2.147009,"eighty":-1.095016,"marketCap":15963355},{"date":"2024-10-18","current":-1.260232,"twenty":-7.355439,"median":-2.135501,"eighty":-1.1102,"marketCap":16111164},{"date":"2024-10-25","current":-1.437761,"twenty":-7.355439,"median":-2.125705,"eighty":-1.110817,"marketCap":18380747},{"date":"2024-10-31","current":-2.79918,"twenty":-7.270245,"median":-2.125705,"eighty":-1.18937,"marketCap":35785525},{"date":"2024-11-08","current":-2.150279,"twenty":-7.139233,"median":-2.135501,"eighty":-1.21299,"marketCap":27489790},{"date":"2024-11-15","current":-2.170683,"twenty":-7.064784,"median":-2.135501,"eighty":-1.218696,"marketCap":24399222},{"date":"2024-11-22","current":-1.856409,"twenty":-6.974663,"median":-2.135501,"eighty":-1.224412,"marketCap":20866673},{"date":"2024-11-29","current":-1.90061,"twenty":-6.755235,"median":-2.115909,"eighty":-1.229612,"marketCap":21363499},{"date":"2024-12-06","current":-1.753275,"twenty":-6.551481,"median":-2.101597,"eighty":-1.233136,"marketCap":19707413},{"date":"2024-12-13","current":-1.650142,"twenty":-6.445215,"median":-2.081117,"eighty":-1.235736,"marketCap":18548154},{"date":"2024-12-20","current":-1.473341,"twenty":-6.405718,"median":-2.071827,"eighty":-1.237108,"marketCap":16560852},{"date":"2024-12-27","current":-1.768009,"twenty":-6.252529,"median":-2.060335,"eighty":-1.241733,"marketCap":19873022},{"date":"2025-01-03","current":-1.694342,"twenty":-5.991992,"median":-2.057134,"eighty":-1.250581,"marketCap":19044979},{"date":"2025-01-10","current":-1.959543,"twenty":-5.868974,"median":-2.057134,"eighty":-1.258227,"marketCap":22025933},{"date":"2025-01-17","current":-1.768009,"twenty":-5.779566,"median":-2.037542,"eighty":-1.258227,"marketCap":19873022},{"date":"2025-01-24","current":-1.664875,"twenty":-5.732546,"median":-2.035768,"eighty":-1.259831,"marketCap":18713762},{"date":"2025-01-31","current":-1.856409,"twenty":-5.367769,"median":-2.010846,"eighty":-1.260232,"marketCap":20866673},{"date":"2025-02-07","current":-1.723809,"twenty":-5.033478,"median":-1.997597,"eighty":-1.260232,"marketCap":19376196},{"date":"2025-02-14","current":-1.753275,"twenty":-4.268723,"median":-1.967235,"eighty":-1.268496,"marketCap":19707413},{"date":"2025-02-21","current":-1.635408,"twenty":-4.064306,"median":-1.959359,"eighty":-1.271301,"marketCap":18382545},{"date":"2025-02-28","current":-1.502808,"twenty":-3.940055,"median":-1.950359,"eighty":-1.271793,"marketCap":16892069},{"date":"2025-03-07","current":-1.488074,"twenty":-3.869935,"median":-1.934829,"eighty":-1.271793,"marketCap":16726460},{"date":"2025-03-14","current":-1.841676,"twenty":-3.869935,"median":-1.920187,"eighty":-1.27873,"marketCap":20701065},{"date":"2025-03-21","current":-1.797476,"twenty":-3.846869,"median":-1.893243,"eighty":-1.290292,"marketCap":20204239},{"date":"2025-03-28","current":-1.620675,"twenty":-3.823803,"median":-1.885876,"eighty":-1.294917,"marketCap":18216937},{"date":"2025-04-04","current":-1.927027,"twenty":-3.8033,"median":-1.893243,"eighty":-1.309909,"marketCap":15132288},{"date":"2025-04-11","current":-1.806267,"twenty":-3.701093,"median":-1.885876,"eighty":-1.319904,"marketCap":14183998},{"date":"2025-04-17","current":-2.291021,"twenty":-3.602316,"median":-1.885876,"eighty":-1.323783,"marketCap":17990609}],"updateTime":1745094857217}}}